EXECUTION VERSION CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[*******]” OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO...Distribution and Sublicense Agreement • May 5th, 2020 • New York
Contract Type FiledMay 5th, 2020 JurisdictionTHIS DISTRIBUTION AND SUBLICENSE AGREEMENT (this “Agreement”), dated as of February 1, 2016 (the “Effective Date”), by and between Braeburn Pharmaceuticals, inc., a corporation formed under the laws of Delaware (“Braeburn”), and Knight Therapeutics Inc., a corporation incorporated under the laws of Canada (“Knight”).
DISTRIBUTION AND SUBLICENSE AGREEMENTDistribution and Sublicense Agreement • August 14th, 2018 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledAugust 14th, 2018 Company Industry JurisdictionTHIS DISTRIBUTION AND SUBLICENSE AGREEMENT (this “Agreement”), dated as of February 1, 2016 (the “Effective Date”), by and between Braeburn Pharmaceuticals, inc., a corporation formed under the laws of Delaware (“Braeburn”), and Knight Therapeutics Inc., a corporation incorporated under the laws of Canada (“Knight”).